In turn, similar baseline and follow-up levels of cardiometabolic risk factors in women declining pharmacotherapy of iatrogenic prolactin excess and in untreated women with normal prolactin levels argue against adaptive changes in response to prolactin excess. This evidence concerns the gene PRL and Increased circulating prolactin concentration.